“AI in clinical and molecular diagnostics uses artificial intelligence to analyze medical data, such as lab tests and genetic information, more quickly and accurately. BCC Research Highlights Explosive Growth in AI-Driven Clinical and Molecular Diagnostics, Projecting Market Expansion from $2.6 Billion in 2024 to $8.9 Billion by 2029
BOSTON, Jan. 9, 2025 /PRNewswire/ — According to the latest study from BCC Research AI in Clinical and Molecular Diagnostics Market is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.
This report provides an overview of the global market for AI in clinical and molecular diagnostics, covering market size, growth trends, and key applications such as medical imaging, genomics, and lab testing. It focuses on the factors driving AI adoption, challenges, and opportunities, along with profiles of leading companies and regional insights. Emerging trends in personalized medicine and telehealth are also discussed, making this report a valuable resource for healthcare providers, tech developers, and policymakers.
Interesting and surprising facts:
Two Powerful Ways AI is Revolutionizing Healthcare Diagnostics
- Predicting Disease Before Symptoms Appear
AI can analyze your genetic data to identify potential health risks, even before you show any symptoms. This means doctors can take preventive measures to keep you healthy. - Unlocking Hidden Insights in Medical Records
AI’s language processing abilities allow it to read and understand doctor’s notes, extracting valuable information that might have been overlooked. This helps doctors make more accurate diagnoses, develop personalized treatment plans and improve patient care.
Factors contributing to the growth include:
- Investment in the AI health sector.: Investment in the AI health sector involves funding AI technologies that help doctors diagnose diseases quicker, and improve treatments and healthcare efficiency. Companies, governments, and organizations are investing more in AI to boost patient care and lower costs.
- Increasing prevalence of chronic and infectious diseases.: The rising number of chronic diseases (such as diabetes and heart disease) and infectious diseases (such as flu and COVID-19) is putting stress on healthcare systems, creating a greater demand for improved treatments and prevention methods.
- Introduction of software with AI.: The introduction of AI-powered software means that new programs can learn from data, make decisions, and perform tasks such as analyzing medical images or diagnosing diseases more accurately and efficiently, making processes faster and smarter.
- Opportunities in developing markets.: Opportunities in developing markets refer to the potential for businesses to grow in countries with expanding economies, especially in sectors such as healthcare and technology. Companies can invest by offering products or services, such as AI in healthcare, to meet growing demand and improve living standards in these regions.
Sample Copy of the AI in Clinical and Molecular Diagnostics Market Report
Report Synopsis
Report Metric | Details |
Base year considered | 2023 |
Forecast period considered | 2024-2029 |
Base year market size | $2.3 billion |
Market size forecast | $8.9 billion |
Growth rate | CAGR of 27.6% for the forecast period of 2024-2029 |
Segments covered | Type, Component, and Region |
Regions covered | North America, Europe, Asia-Pacific, and Rest of the World |
Countries covered | U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, China, India, Japan, Australia, Singapore, South Korea |
Market drivers | • Investment in the AI health sector • Increasing prevalence of chronic and infectious diseases • Introduction of software with AI • Opportunities in developing markets |
This report addresses the following key questions:
- What is the projected size and growth rate of the global market for AI in clinical and molecular diagnostics?
The market is projected to grow from $2.6 billion in 2024 to $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period. - Which market segments are covered in the report?
The AI in clinical and molecular diagnostics market is segmented based on type, component, and region. - By type, which segment will dominate the market by the end of 2029?
By type, molecular diagnostics is expected to contribute the highest share of the market by the end of 2029. - Which component is growing fastest?
Software is the fastest growing component.
Leading companies in the market include:
- Atomwise Inc.
- F. Hoffmann-La Roche Ltd.
- Fujifilm Holdings Corp.
- GE Healthcare
- Illumina Inc.
- Koninklijke Philips N.V.
- Medtronic
- Microsoft Corp.
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
- Butterfly Network Inc.
- Enlitic
- Intel Corp.
- Merative
- Nvidia Corp.
- Qure.Ai
- Synapsica Healthcare Pvt Ltd.
Directly purchase a copy of the report from BCC Research.
For further information on these reports or to purchase one, please contact [email protected].
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts’ goal is to help readers make informed business decisions, free of noise and hype.
Contact Us
Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA
Email: [email protected],
Phone: +1 781-489-7301
For media inquiries, email [email protected] or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg
SOURCE BCC Research LLC
